Between three and six million noses a year are affected by allergic rhinitis in the United Kingdom1. Symptoms are so severe that a guesstimate of five million prescriptions are dispensed for this condition (DHSS Research and Statistical Services, unpublished data) apart from numerous over-the-counter and home remedies. The annual direct cost to the Exchequer of these drugs is £19 million, excluding the cost of medical attention and absence from work. Many of these drugs are inappropriate and until the underlying basis of the immunopharmacology of this disease is unravelled it will not thereby be improved.
Nasal mast cells Against this background, Dr Robert Davies (St Bartholomew's Hospital, London) assessed the integral role of the mast cell in the pathogenesis of this mysterious disease. More mast cells seem to be present in nasal secretions during the pollen season2 and the therapeutic success of antihistamine in the treatment of allergic rhinitis suggests that the histamine-secreting mast cell is of overriding importance. Both the immediate3 and late4 nasal obstructive responses to allergic challenge are associated with an increase in nasal lavage histamine content. Histamine irritation in the nose can reproduce many of the symptoms of this condition, inducing tickling, sneezing, presumably following stimulation of the afferent nerve endings of the trigeminal nerve', rhinorrhoea and nasal blockage. The effects ofhistamine on membrane permeability and nasal airway resistance are well-established6, but Dr Davies has shown an increase in histamine content of nasal secretions to methacholine and, to a lesser extent, to the common cold. This suggests that ordinary nasal secretions have high levels of histamine independent of mast cell content. This 'cell-free' histamine may be a product of the metabolism of such bacteria as Haemophilus influenzae. The dose-related increase in nasal airway resistance to histamine challenge is greater in active rhinitics than non-rhinitics, which may be considered as a manifestation of hyperreactivity ofthe nasal airways similar to that occurring in the lower airways in patients with asthma. Challenge with methacholine does not lead to any increase in nasal airway resistance but does cause greater secretion in patients with rhinitis compared to those without.
Inferior turbinate biopsy shows that the disposition of mature mast cells, recognized by the presence of chloracetate esterase, is concentrated around capillaries, although a few mast cells are found in the pseudo-stratified epithelium. However, the characteristics of mast cells may differ in different parts of the nose. The majority of nasal mast cells have many of the characteristics of the 'mucosal type' mast cell originally described in the rat intestine7 rather than the connective tissue variety or even the heparincontaining basophil. For example, they do not counterstain with safranine, staining is blocked when tissues are fixed in formal-buffered saline (pH 7.0) and they do not release histamine in response to the polyamine 48/80. Whether or not there is true heterogeneity in the mast cell population in the human nasal mucous membrane requires more sophisticated evaluation.
The central role of the nasal mast cell in allergic rhinitis is again suggested by the cell's ability to release histamine when incubated with anti-IgE. Eight patients with allergic rhinitis were challenged in one nostril with allergen which resulted in degranulation of 70% of the mast cells; the control nostril was treated with saline and this resulted in degranulation of only 15%. Electron microscopy studies showed degranulation within 20 minutes of exposure, up to 1 mm depth from the mucosal surface. This may result from rapid absorption of allergen or from nervous reflex release of substance P from nerve endings closely related to mast cellsthough release of the latter is often accompanied by pain, which is not a feature of rhinitis. The phenomenon of nasal priming was discussed, as was the relevance of the greater numbers of mast cells in atopic patients8.
A technique of computerized visualization was described to calculate mast cell content/mm3, enabling the serial assays to demonstrate changes in number. Accurate quantification of nasal mast cell numbers in 7 patients submitted to biopsy before, during and after seasonal pollen exposure, showed a fourfold increase at the height ofthe season. Whether this increase in mast cell numbers is regulated by interleukin-III secretion, which in turn is under lymphocyte control, or other nervous or cellular influences remains to be determined.
Chemical mediators
Certainly, polymorphs and eosinophils present in the nasal mucosa and secretions should not be regarded as bystanders in allergic rhinitis, since these cells can release potent chemical mediators, as shown by Dr Rory Shaw (St Mary's Hospital, London). Amongst those generated from the cell membranes are the sulphidopeptide leukotrienes (LTC4, LTD4 and LTE4) which in vitro stimulate mucus production, alter vascular permeability and tone and increase nasal blood flow when administered topically to the nose9. Release of LTC4, LTD4, LTE4, and to a lesser extent the 'chemotactic' leukotriene B4, into the nasal secretions has been shown to occur following nasal provocation with the house-dust mite extract allergen but not with methacholine10.
Although leukotrienes are generated by mast cells following IgE-dependent stimulation, eosinophils, Report of meeting of Section of Clinical Immunology the predominant cell in chronic rhinitis, also have the capacity to synthesize the sulphidopeptide leukotrienes and enhance the release of leukotrienes from mast cells, so that they could also play a role in the pathogenesis of chronic rhinitis". In addition, the arachidonic acid metabolite, prostaglandin D2, thought to be a specific mast cell product, has also been identified in nasal secretions following allergen provocation'2* Chemicals present within the granules of mast cells and basophils, including histamine and the enzyme TAME-esterase, may simultaneously be released into nasal secretions following allergen challenge. Other preformed mediators identified in nasal secretions following allergen challenge include kininogens, the substrate for kinin generations, and high molecular weight neutrophil chemotactic factor'3 which may contribute to the influx of inflammatory cells'4. These cells may contribute to a late reaction during which there may be a second increase in the concentrations of histamine, TAMEesterase activity and kinins in nasal secretions3. In addition to improving our understanding of the pathophysiology of rhinitis, these studies may shed light on similar events occurring in less accessible airways of asthma.
Fallacy of the nasalpolypus Mr Adrian Drake-Lee (Royal United Hospital, Bath) addressed himself to the commonly held concept that polyps result from an allergic response, which he believes is erroneous. This concept is based on nonspecific clinical symptomatology, the association with late-onset asthma, the presence of tissue eosinophilia and levels of IgE within polyp fluid. The last finding may reflect the high levels normally present in nasal mucosa. He has examined patients suffering from nasal polyposis to establish an atopic profile. Only the incidence of hypersensitivity and late-onset asthma were greater in the 'polyp' patients compared with normal controls, suggesting that atopy is a coincidental phenomenon, and there does not appear to be an atopic subgroup.
To decide on the role ofmast cells in the polyps, Mr Drake-Lee observed degranulation of these cells by electron microscopy in polyps in 20 cases and in the inferior turbinates in 15 cases. He further presented the results of the constituents of polyp oedema fluid compared with matched sera. Histamine levels were markedly raised (1700 ng/ml:polyp compared with 10 ng/ml:serum) but there was little difference between total IgG4 levels (114 ng/ml), total IgE and allergen-specific IgE of IgG4; he therefore concluded that mast cell degranulation is central to polyp formation and allergy does not contribute. Mr Drake-Lee said during questioning that he had not encountered any basophils in polyp fluids.
Corticosteroids as treatment
Professor Romain Pauwels (State University Academic Hospital, Ghent, Belgium) considered the molecular, cellular and pharmacological activity of corticosteroids in the treatment of rhinitis.
The now generally accepted theory on the molecular action of glucocorticosteroids stresses the nuclear pathway of action' 5. The glucocorticoid molecule passively diffuses through the cell mem-brane into the cytoplasm of the cell where the glucocorticoid molecule and steroid receptor are stereospecific, and the stronger the binding capacity of the glucocorticoid molecule the stronger will be the glucocorticoid effect.
The glucocorticoid receptor binding results in a change of the steric conformation of the receptor molecule. The glucocorticosteroid-receptor complex then moves to the cellular nucleus and binds to specific sites on the DNA molecules. These DNA structures are supposed to enhance DNA transcription. It looks as if these steroid-specific enhancers may stimulate the transcription of different DNA sequences, resulting in the formation of different mRNA molecules. The mRNA molecules then move to the cytoplasm, where they are translated by the ribosomes into proteins.
The result of the nuclear pathway of glucocorticoid action is the formation ofdifferent proteins. The whole process may take several hours. It has long been suspected that the nuclear pathway would not explain all the activities of the glucocorticoids. Indeed, some of their actions appear faster than could be expected through DNA activation. It is therefore probable that glucocorticoids also act in the cytoplasm by direct action on the Ca+ + influx or by interference with the phosphorylation of proteins. It is not known if this non-nuclear pathway needs to bind with the steroid receptor. The link between the molecular action of glucocorticosteroids and their clinical efficacy is not clear.
Glucocorticoids have a variety of cellular activities which may be relevant to their efficacy in patients with rhinitis. In low concentrations, glucocorticoids inhibit the IgE-mediated release of histamine from human basophils if preincubated for 24 hours'6. Glucocorticoids do not, however, have the same inhibiting capacity on purified human lung mast cells'7. Preincubation of mouse bone marrowderived mast cells with dexamethasone for 24 hours inhibits the antigen-IgE induced secretion of betahexosaminidase, LTC4 and LTB4 but enhances the release of PGD2'8. Glucocorticoids also inhibit the release of lysosomal enzymes and prostaglandins from neutrophils. It is generally thought that the inhibitory activity of glucocorticosteroids on prostaglandin synthesis is partially responsible for their vasoconstrictory and anti-oedematous effect. Glucocorticoids also decrease the adherence ofneutrophils and eosinophils to inflamed vascular endothelium, decrease the neutrophilic and eosinophilic response to chemotactic factors and inhibit the release of various inflammatory factors from these cells.
Glucocorticoids have several pharmacological activities that are relevant to their long-term effect in rhinitis'9. Glucocorticoids inhibit the late reaction following nasal allergen challenge. The selective effect ofglucocorticoids on basophils, and not on connective tissue mast cells, further supports a possible role of basophils in the late reaction in the nose. However, glucocorticoids also reduce the influx of secondary cells such as eosinophils and neutrophils, attracted by previous mast cell activation. Glucocorticosteroids reduce the number of basophilic cells on the epithelial surface of the nose and diminish the nasal eosinophilia in patients with chronic rhinitis. They also decrease the sensitivity of irritant receptors and reduce the secretory response to stimulation of cholinergic receptors.
New antihistamines
The role of the newer generation antihistamines was presented by Dr Peter Howarth (London Hospital). Many of the older antihistamines, however, possess other actions such as anticholinergic, local anaesthetic, antiserotonin and alpha-adrenoceptor antagonist activities. It may be difficult to disentangle their precise mode ofaction, while their associated central sedative effects often make them unacceptable to patients as regular medication.
The recent advent oftwo newer Hi-receptor antagonists, terfenadine and astemizole, have overcome many of these problems. Both are specific Hireceptor antagonists and, unlike oxacetamide, are devoid of sedative actions20'21. They differ in that terfenadine is rapidly absorbed, undergoes extensive first-pass metabolism, has a rapid onset of clinical benefit and requires a twice-daily dosage because of a shorter duration of action. Astemizole, by contrast, while also being rapidly absorbed, has a prolonged half-life, exerting an effect on histamine skin weal formation from 2 hours to 32 days after a single oral 40 mg dose22. In view ofthe prolonged half-life (about 15 days), there is increasing clinical benefit until maximum serum levels are achieved. This occurs after four weeks with 10 mg/day or after two weeks with 30mg/day for the first week and 10mg/day thereafter. With maximum therapeutic levels there is almsot complete inhibition of histamine skin weal formation (50 jg/ml histamine acid-phosphate23). The clinical application of these two Hi-receptor antagonists differs. Terfenadine is suited for intermittent and acute symptomatic therapy, whilst astemizole is ideal for maintenance or prolonged therapy. This has been confirmed in several-clinical trials employing these agents in the treatment of seasonal allergic rhinitis. Terfendadine has been shown to have a quicker onset ofclinical benefit than astemizole24. Both are of equal benefit after one week of regular treatment (terfenadine 60 mg twice daily, astemizole 10 mg/day) while astemizole is significantly better than terfenadine if treatment is continued beyond two weeks25'26. Using astemizole it has been possible to explore the role of histamine in seasonal allergic rhinitis. When treatment is started before the pollen season, astemizole limits the development of sneezing and rhinorrhea in patients with nasal blockage23'25. Symptoms are not completely eradicated, suggesting that mediators other than histamine contribute to the genesis of sneezing and rhinorrhea as well as blocked nose. Similarly, astemizole almost completely inhibits the skin weal response by 500/o, again implying that nonhistamine mediators are involved in the immediate allergic response23'25. Recently the release of nonhistamine mediators, including the sulphidopeptide leukotrienes LTC4 and LTD4, PGD2 and kinins, have been found in the immediate nasal response to allergic challenge (see above). Since corticosteroids have been shown to inhibit the release of eicosanoids (leukotrienes and prostaglandins) through an action on phospholipase A2 (see above), astemizole combined with a nasal corticosteroids may improve clinical control of seasonal allergic rhinitis.
To investigate this, 65 patients with seasonal allergic rhinitis were randomly allocated to receive maintenance treatment throughout the pollen season with either astemizole and beclomethasone dipropionate (100 jig per nostril twice daily) or astemizole and nasal placebo propellant (2 puffs for each nostril twice daily). Astemizole therapy in all patients was 30 mg more, for the first week and 10 mg/daily thereafter, with all patients starting treatment as a cohort before the onset of the pollen season. Subjective reporting of symptoms or daily visual analogue scales identified that the combination therapy was significantly better than astemizole alone in preventing the development of sneezing (P<0.02), rhinorrhea (P<0.02) and nasal blockage (P<0.001). Serial measurement of total nasal resistance by body plethysmography in these patients throughout the pollen season objectively confirmed the subjective findings with respect to nasal obstruction. The combination therapy was found acceptable by patients, with 86% rating it 8 or greater on a sale of 0-10, in which 0=useless and 10=superb and could not be bettered.
The combination therapy with astemizole and beclomethasone diproprionate, taken on a regular basis, is effective in eradicating all nasal symptoms associated with hay fever. The effect of corticosteroids alone will have to be evaluated.
Nedocromil
The role of nedocromil was discussed by Dr Oliver Corrado (St Bartholomew's Hospital, London). Nedocromil sodium is a pyranoquinolone dicarboxylic acid derivative which has been shown in vitro and in vivo animal models to inhibit allergic and inflammatory reactions27-30. The results of a double-blind, placebo-controlled, crossover design study were presented in 10 patients with allergic rhinitis. An allergic aetiology of their rhinitis was determined by a clinical history supported by positive skin-prick tests and nasal provocation tests with the relevant allergen, this being grass pollen in 8 and cat fur extract in 2. On entry into the study each patient underwent nasal provocation with allergen to establish the concentration of allergen producing a positive nasal response, defined as at least two of the following: greater or equal to three times increase in total nasal airway resistance, five sneezes or 0.5 ml of secretion.
This allergen concentration was readministered on two subsequent weekly occasions 20 minutes after intranasal pretreatment (one spray to each nostril) with either nedocromil sodium (1%) or placebo. Following allergen provocation three variables were recorded: the number of sneezes, the volume of nasal secretion produced and the change in nasal airway resistance measured by passive anterior rhinomanometry. Nedocrimil sodium was significantly more effective than placebo in preventing allergen-induced nasal obstruction, rhinorrhoea and sneezing. Inhaled nedocromil sodium can treat allergic rhinitis.
Role of hyposensitization: vaccines
In the final presentation, Dr Lawrence Youlten (Guy's Hospital, London) re-examined the role of hyposensitization in allergic rhinitis, a treatment which has been available for 70 years. Several wellcontrolled studies point to some clinical efficacy in allergic rhinitis, particularly the seasonal variety related to pollens. Much recent effort has gone into making hyposensitization with vaccines safer whilst retaining efficacy, with purification and standardization of allergens. The natural history of seasonal allergic rhinitis often includes periods of spon-taneous improvement and this, along with other factors, is associated with a relatively high placebo response in many studies. To demonstrate any clinical improvement with new vaccines, large numbers and multicentre studies are required, with all their attendant problems. For this reason, many attempts have been made to identify objective criteria oftreatment efficacy such as quantitative skin tests and conjunctival or nasal provocation31'32.
Alternative routes to injection have been explored, including the nasal route. The oral route has recently been shown to be useful for some allergens, though the lack ofhomogeneity of allergen extracts makes it hard to extrapolate from one type to another.
Conclu8ion
Until recently, allergic rhinitis has failed to provoke the interest generated by other respiratory problems. The areas of research discussed at this meeting demonstrate an encouraging, albeit overdue, response to a neglected condition and may have general relevance to the mechanism of alllergy.
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